Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2

Bishoy El-Aarag, Tomonari Kasai, Junko Masuda, Hussein Agwa, Magdy Zahran, Masaharu Seno

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Lung cancer is one of the major causes of cancer-related mortality worldwide, and non-small-cell lung cancer is the most common form of lung cancer. Several studies had shown that thalidomide has potential for prevention and therapy of cancer. Therefore, the current study aimed to investigate the antitumor effects of two novel thalidomide analogs in human lung cancer A549 cells. The antiproliferative, antimigratory, and apoptotic effects in A549 cells induced by thalidomide analogs were examined. In addition, their effects on the expression of mRNAs encoding vascular endothelial growth factor165 (VEGF165) and matrix metalloproteinase-2 (MMP-2) were evaluated. Their influence on the tumor volume in nude mice was also determined. Results revealed that thalidomide analogs exhibited antiproliferative, antimigratory, and apoptotic activities with more pronounced effect than thalidomide drug. Furthermore, analogs 1 and 2 suppressed the expression levels of VEGF165 by 42% and 53.2% and those of MMP-2 by 45% and 52%, respectively. Thalidomide analogs 1 and 2 also reduced the tumor volume by 30.11% and 53.52%, respectively. Therefore, this study provides evidence that thalidomide analogs may serve as a new therapeutic option for treating lung cancer.

Original languageEnglish
Pages (from-to)549-555
Number of pages7
JournalBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Volume85
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Thalidomide
Matrix Metalloproteinase 2
Vascular Endothelial Growth Factor A
Lung Neoplasms
Tumor Burden
Blood Vessels
Growth
A549 Cells
Nude Mice
Non-Small Cell Lung Carcinoma
Neoplasms
Messenger RNA
Mortality
Therapeutics
Pharmaceutical Preparations

Keywords

  • A549 cancer cells
  • Anticancer
  • MMP-2
  • Thalidomide analogs
  • VEGF

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{c997559a0c894ed0b6e4116b857e85d3,
title = "Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2",
abstract = "Lung cancer is one of the major causes of cancer-related mortality worldwide, and non-small-cell lung cancer is the most common form of lung cancer. Several studies had shown that thalidomide has potential for prevention and therapy of cancer. Therefore, the current study aimed to investigate the antitumor effects of two novel thalidomide analogs in human lung cancer A549 cells. The antiproliferative, antimigratory, and apoptotic effects in A549 cells induced by thalidomide analogs were examined. In addition, their effects on the expression of mRNAs encoding vascular endothelial growth factor165 (VEGF165) and matrix metalloproteinase-2 (MMP-2) were evaluated. Their influence on the tumor volume in nude mice was also determined. Results revealed that thalidomide analogs exhibited antiproliferative, antimigratory, and apoptotic activities with more pronounced effect than thalidomide drug. Furthermore, analogs 1 and 2 suppressed the expression levels of VEGF165 by 42{\%} and 53.2{\%} and those of MMP-2 by 45{\%} and 52{\%}, respectively. Thalidomide analogs 1 and 2 also reduced the tumor volume by 30.11{\%} and 53.52{\%}, respectively. Therefore, this study provides evidence that thalidomide analogs may serve as a new therapeutic option for treating lung cancer.",
keywords = "A549 cancer cells, Anticancer, MMP-2, Thalidomide analogs, VEGF",
author = "Bishoy El-Aarag and Tomonari Kasai and Junko Masuda and Hussein Agwa and Magdy Zahran and Masaharu Seno",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.biopha.2016.11.063",
language = "English",
volume = "85",
pages = "549--555",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2

AU - El-Aarag, Bishoy

AU - Kasai, Tomonari

AU - Masuda, Junko

AU - Agwa, Hussein

AU - Zahran, Magdy

AU - Seno, Masaharu

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Lung cancer is one of the major causes of cancer-related mortality worldwide, and non-small-cell lung cancer is the most common form of lung cancer. Several studies had shown that thalidomide has potential for prevention and therapy of cancer. Therefore, the current study aimed to investigate the antitumor effects of two novel thalidomide analogs in human lung cancer A549 cells. The antiproliferative, antimigratory, and apoptotic effects in A549 cells induced by thalidomide analogs were examined. In addition, their effects on the expression of mRNAs encoding vascular endothelial growth factor165 (VEGF165) and matrix metalloproteinase-2 (MMP-2) were evaluated. Their influence on the tumor volume in nude mice was also determined. Results revealed that thalidomide analogs exhibited antiproliferative, antimigratory, and apoptotic activities with more pronounced effect than thalidomide drug. Furthermore, analogs 1 and 2 suppressed the expression levels of VEGF165 by 42% and 53.2% and those of MMP-2 by 45% and 52%, respectively. Thalidomide analogs 1 and 2 also reduced the tumor volume by 30.11% and 53.52%, respectively. Therefore, this study provides evidence that thalidomide analogs may serve as a new therapeutic option for treating lung cancer.

AB - Lung cancer is one of the major causes of cancer-related mortality worldwide, and non-small-cell lung cancer is the most common form of lung cancer. Several studies had shown that thalidomide has potential for prevention and therapy of cancer. Therefore, the current study aimed to investigate the antitumor effects of two novel thalidomide analogs in human lung cancer A549 cells. The antiproliferative, antimigratory, and apoptotic effects in A549 cells induced by thalidomide analogs were examined. In addition, their effects on the expression of mRNAs encoding vascular endothelial growth factor165 (VEGF165) and matrix metalloproteinase-2 (MMP-2) were evaluated. Their influence on the tumor volume in nude mice was also determined. Results revealed that thalidomide analogs exhibited antiproliferative, antimigratory, and apoptotic activities with more pronounced effect than thalidomide drug. Furthermore, analogs 1 and 2 suppressed the expression levels of VEGF165 by 42% and 53.2% and those of MMP-2 by 45% and 52%, respectively. Thalidomide analogs 1 and 2 also reduced the tumor volume by 30.11% and 53.52%, respectively. Therefore, this study provides evidence that thalidomide analogs may serve as a new therapeutic option for treating lung cancer.

KW - A549 cancer cells

KW - Anticancer

KW - MMP-2

KW - Thalidomide analogs

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=85011965332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011965332&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2016.11.063

DO - 10.1016/j.biopha.2016.11.063

M3 - Article

C2 - 27889230

AN - SCOPUS:85007223419

VL - 85

SP - 549

EP - 555

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

ER -